Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.
Market Cap | 3.155 Billion | Shares Outstanding | 96.629 Million | Avg 30-day Volume | 1.341 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.45 |
Price to Revenue | 35.1086 | Debt to Equity | 0.1836 | EBITDA | -239.045 Million |
Price to Book Value | 4.1282 | Operating Margin | -412.5427 | Enterprise Value | 1.922 Billion |
Current Ratio | 6.547 | EPS Growth | -0.118 | Quick Ratio | 6.359 |
1 Yr BETA | 2.0511 | 52-week High/Low | 92.7 / 17.1 | Profit Margin | -371.7295 |
Operating Cash Flow Growth | -100.2188 | Altman Z-Score | 4.5604 | Free Cash Flow to Firm | -291.023 Million |
Earnings Report | 2022-11-03 |
Please sign in first
none
65 Thousand total shares from 8 transactions
61.2 Thousand total shares from 5 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
WOLCHKO J SCOTT PRESIDENT AND CEO |
|
869,338 | 2022-07-21 | 10 |
VALAMEHR BAHRAM CHIEF R&D OFFICER |
|
192,990 | 2022-07-07 | 9 |
PLAVSIC MARK CHIEF TECHNICAL OFFICER |
|
127,123 | 2022-07-05 | 3 |
POWL BRIAN T. CHIEF COMMERCIAL OFFICER |
|
115,000 | 2022-06-27 | 2 |
|
629,317 | 2022-06-09 | 1 | |
|
178,634 | 2022-06-09 | 3 | |
|
22,552 | 2022-06-09 | 2 | |
|
78,175 | 2022-06-09 | 2 | |
|
12,980,446 | 2022-06-09 | 1 | |
|
22,383 | 2022-06-09 | 4 | |
|
23,224 | 2022-06-09 | 1 | |
|
21,741 | 2022-06-09 | 2 | |
|
25,287 | 2022-06-09 | 1 | |
TAHL CINDY GENERAL COUNSEL AND SECRETARY |
|
243,361 | 2022-06-01 | 6 |
CHU YU-WAYE CHIEF MEDICAL OFFICER |
|
151,033 | 2022-04-19 | 5 |
DULAC EDWARD J III CHIEF FINANCIAL OFFICER |
|
194,994 | 2022-01-25 | 6 |
|
23,224 | 2021-06-09 | 0 | |
SHOEMAKER DANIEL D CHIEF SCIENTIFIC OFFICER |
|
73,020 | 2021-03-08 | 0 |
|
2,310,432 | 2019-07-31 | 0 | |
ABBOT STEWART CHIEF DEVELOPMENT OFFICER |
|
64,917 | 2018-05-15 | 0 |
STORGARD CHRIS CHIEF MEDICAL OFFICER |
|
0 | 2018-01-16 | 0 |
|
0 | 2017-05-02 | 0 | |
FATE THERAPEUTICS INC CHIEF SCIENTIFIC OFFICER |
|
103,816 | 2016-01-08 | 0 |
WEYER CHRISTIAN SEE REMARKS |
|
30,429 | 2015-04-13 | 0 |
MULTANI PRATIK S CHIEF MEDICAL OFFICER |
|
3,024 | 2015-01-05 | 0 |
FLYNN PETER D SEE REMARKS |
|
6,505 | 2015-01-05 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-07-25 18:18:08 -0400 | 2022-07-22 | M | 6,246 | d | 0 | direct | yes | |||||||||
2022-07-25 18:18:08 -0400 | 2022-07-22 | S | 620 | $33.28 | d | 431,546 | direct | yes | 5.7043 | -2.3901 | 5.7043 | 2 | -4.2702 | 5 | ||
2022-07-25 18:18:08 -0400 | 2022-07-22 | S | 2,703 | $32.61 | d | 432,166 | direct | yes | 5.7043 | -2.3901 | 5.7043 | 2 | -4.2702 | 5 | ||
2022-07-25 18:18:08 -0400 | 2022-07-22 | S | 2,923 | $31.33 | d | 434,869 | direct | yes | 5.7043 | -2.3901 | 5.7043 | 2 | -4.2702 | 5 | ||
2022-07-25 18:18:08 -0400 | 2022-07-22 | M | 6,246 | $2.70 | a | 437,792 | direct | yes | 5.7043 | -2.3901 | 5.7043 | 2 | -4.2702 | 5 | ||
2022-07-25 18:18:08 -0400 | 2022-07-21 | M | 30,000 | d | 6,246 | direct | yes | |||||||||
2022-07-25 18:18:08 -0400 | 2022-07-21 | S | 19,171 | $33.07 | d | 431,546 | direct | yes | 5.7043 | -2.3901 | 5.7043 | 2 | -4.2702 | 5 | ||
2022-07-25 18:18:08 -0400 | 2022-07-21 | S | 10,829 | $32.54 | d | 450,717 | direct | yes | 5.7043 | -2.3901 | 5.7043 | 2 | -4.2702 | 5 | ||
2022-07-25 18:18:08 -0400 | 2022-07-21 | M | 30,000 | $2.70 | a | 461,546 | direct | yes | 5.7043 | -2.3901 | 5.7043 | 2 | -4.2702 | 5 | ||
2022-07-08 16:51:04 -0400 | 2022-07-07 | M | 17,158 | $2.73 | d | 13,156 | direct | yes | ||||||||
2022-07-08 16:51:04 -0400 | 2022-07-07 | S | 17,158 | $30.23 | d | 179,834 | direct | yes | 4.4546 | 7.6114 | 11.1891 | 5 | 0.0 | 1 | ||
2022-07-08 16:51:04 -0400 | 2022-07-07 | M | 17,158 | $2.73 | a | 196,992 | direct | yes | 4.4546 | 7.6114 | 11.1891 | 5 | 0.0 | 1 | ||
2022-07-07 16:04:11 -0400 | 2022-07-06 | M | 5,842 | $2.73 | d | 30,314 | direct | yes | ||||||||
2022-07-07 16:04:11 -0400 | 2022-07-06 | M | 2,000 | $4.84 | d | 8,704 | direct | yes | ||||||||
2022-07-07 16:04:11 -0400 | 2022-07-06 | S | 7,842 | $30.07 | d | 179,834 | direct | yes | -4.9983 | 5.6315 | 5.6315 | 6 | -4.9983 | 2 | ||
2022-07-07 16:04:11 -0400 | 2022-07-06 | M | 5,842 | $2.73 | a | 187,676 | direct | yes | -4.9983 | 5.6315 | 5.6315 | 6 | -4.9983 | 2 | ||
2022-07-07 16:04:11 -0400 | 2022-07-06 | M | 2,000 | $4.84 | a | 181,834 | direct | yes | -4.9983 | 5.6315 | 5.6315 | 6 | -4.9983 | 2 | ||
2022-07-06 16:04:56 -0400 | 2022-07-05 | S | 3,719 | $24.61 | d | 127,123 | direct | -2.9745 | 1.8752 | 1.8752 | 6 | -7.8241 | 3 | |||
2022-06-29 17:02:35 -0400 | 2022-06-27 | A | 45,000 | a | 45,000 | direct | 1.4528 | 21.1057 | 36.481 | 37.7724 | 27 | 0.0 | 1 | |||
2022-06-29 17:02:35 -0400 | 2022-06-27 | A | 70,000 | a | 70,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
FATE THERAPEUTICS INC FATE | 2022-08-12 22:15:03 UTC | 2.0234 | 0.2966 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 21:45:04 UTC | 2.0234 | 0.2966 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 21:15:04 UTC | 2.0234 | 0.2966 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 20:45:04 UTC | 2.0117 | 0.3083 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 20:15:05 UTC | 2.0117 | 0.3083 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 19:45:03 UTC | 2.0117 | 0.3083 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 19:15:05 UTC | 2.0117 | 0.3083 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 18:45:03 UTC | 2.013 | 0.307 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 18:15:04 UTC | 2.013 | 0.307 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 17:45:04 UTC | 2.013 | 0.307 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 17:15:05 UTC | 2.013 | 0.307 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 16:45:04 UTC | 2.0088 | 0.3112 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 16:15:04 UTC | 2.0088 | 0.3112 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 15:45:04 UTC | 2.0088 | 0.3112 | 800000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 15:15:05 UTC | 2.0088 | 0.3112 | 800000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 14:45:04 UTC | 2.0088 | 0.3112 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 14:15:05 UTC | 2.0088 | 0.3112 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 13:45:04 UTC | 2.0443 | 0.2757 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 13:15:04 UTC | 2.0443 | 0.2757 | 850000 |
FATE THERAPEUTICS INC FATE | 2022-08-12 12:45:04 UTC | 2.0443 | 0.2757 | 800000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Trust for Professional Managers- Convergence Market Neutral Fund | FATE | -1793.0 shares, $-65265.2 | 2020-08-31 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | FATE | -75.0 shares, $-1665.75 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | FATE | -22.0 shares, $-488.62 | 2020-03-31 | N-PORT |
RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund | FATE | -972.0 shares, $-88092.36 | 2021-01-31 | N-PORT |
Trust for Professional Managers- Convergence Long/Short Equity Fund | FATE | -1091.0 shares, $-60015.91 | 2021-11-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | FATE | -89.0 shares, $-3450.53 | 2022-03-31 | N-PORT |
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | FATE | -1843.0 shares, $-71453.11 | 2022-03-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | FATE | -100.0 shares, $-3877.0 | 2022-03-31 | N-PORT |
Trust for Professional Managers- Convergence Long/Short Equity ETF | FATE | -2037.0 shares, $-47054.7 | 2022-05-31 | N-PORT |
RUSSELL INVESTMENT CO- Sustainable Equity Fund | FATE | -2967.0 shares, $-84737.52 | 2022-04-30 | N-PORT |
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | FATE | -10193.0 shares, $-291112.08 | 2022-04-30 | N-PORT |